Physician profile
Gary Elkin
NPI 1114990678
$4,986.67
in general payments reported to CMS, 2019-2025
29 companies · $664 in 2025
The $664 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $619 · 2021: $395 · 2022: $398 · 2023: $823 · 2024: $797 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,266 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,265.61 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $917.05 | 2019-2025 | |
| Amgen INC. | $639.08 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $513.78 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $382.92 | 2019-2022 | |
| Cvrx, INC. | $348.25 | 2023-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.44 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $317.35 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $315.40 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $226.75 | 2023-2025 | Onyx Frontier, Ffrangio |
| Pfizer INC. | $175.84 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $171.00 | 2019-2024 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $154.77 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $92.76 | 2021-2025 | |
| Esperion Therapeutics, INC. | $62.40 | 2021-2024 | Nexletol |
| Medtronic Vascular, INC. | $61.79 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $40.80 | 2020-2025 | Ecc Solutions |
| Kowa Pharmaceuticals America, INC. | $27.34 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $22.08 | 2019 | |
| Abbott Laboratories | $21.10 | 2023 | Aveir |
| Akcea Therapeutics, INC. | $19.01 | 2019 | |
| Amarin Pharma, INC. | $17.07 | 2020 | |
| Cardiva Medical, INC. | $17.04 | 2021 | |
| Chiesi USA, INC. | $16.11 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $15.47 | 2023 | Arcalyst |
| Astellas Pharma US INC | $15.21 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.07 | 2021 | |
| Terumo Medical Corporation | $13.45 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.17 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Elkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.